CoreAge Rx vs Healthicare
Two GLP-1 providers, one scoreboard. We put CoreAge Rx and Healthicare head-to-head on the published Brief Score — the same six factors, scored the same way.
CoreAge Rx
The verdict
CoreAge Rx takes this head-to-head.
CoreAge Rx scores 94 to 64 on our six-factor Brief Score — CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.
That doesn't make Healthicare a bad call — it's best for readers who want an itemized program quote and can confirm the actual prescription, applicable billing agreement and clinical costs. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both providers scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Compare | CoreAge Rx | Healthicare |
|---|---|---|
| Brief Score | 94/100 (A) | 64/100 (C) |
| Semaglutide | From $79/mo Annual offer: 12 months paid upfront, from $948. Main site: from $99/mo; confirm the selected offer. Full price detailsFrom $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo | $126 monthly or $321.30 quarterly Quarterly advertised equivalent $107.10/month. Published prices exclude California. Exact semaglutide formulation and applicable agreement unconfirmed; older recurring-membership terms differ from no-membership marketing. Full price detailsSemaglutide program listed; exact formulation and complete selected agreement unknown; $126 billed monthly or $321.30 every three months ($107.10/month equivalent), advertised outside California |
| Tirzepatide | From $129/mo Annual offer: 12 months paid upfront, from $1,548. Main site: from $149/mo; confirm the selected offer. Full price detailsFrom $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo | $144 monthly or $367.20 quarterly Quarterly advertised equivalent $122.40/month; named compounded program. Published prices exclude California. Applicable agreement and refund milestones unconfirmed; do not equate monthly billing with the terms’ twenty-eight-to-thirty-day cycle. Full price detailsCompounded tirzepatide program listed; complete selected agreement unknown; $144 billed monthly or $367.20 every three months ($122.40/month equivalent), advertised outside California |
| Coverage | US only; restrictions by state, confirmed at intake | Published medication prices apply to U.S. states except California; clinician and pharmacy eligibility still require confirmation |
| Brand-name access | Not confirmed | Branded comparisons and a separate Wegovy link do not establish the current branded terms of the reviewed semaglutide/tirzepatide programs. |
| Oral / sublingual | Injection only | Unconfirmed |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
CoreAge Rx: The checked annual-plan offer starts at $79/$129 per month on annual prepay; the main product pages still show $99/$149. Confirm the selected offer.
Healthicare: Published outside California: semaglutide $126 monthly/$321.30 quarterly; tirzepatide $144 monthly/$367.20 quarterly. Exact selected agreement and semaglutide formulation require confirmation.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.